6 results on '"genital squamous cell carcinoma"'
Search Results
2. Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors.
- Author
-
Schellenbacher, Christina, Shafti-Keramat, Saeed, Huber, Bettina, Fink, Dieter, Brandt, Sabine, and Kirnbauer, Reinhard
- Subjects
- *
PAPILLOMAVIRUS diseases , *VIRUS-like particles , *EQUIDAE , *GENITALIA tumors , *IN vitro studies - Abstract
The consistent and specific presence of Equus caballus papillomavirus type 2 (EcPV2) DNA and mRNA in equine genital squamous cell carcinoma (gSCC) is suggestive of an etiological role in tumor development. To further validate this concept, EcPV2-neutralizing serum antibody titers were determined by an EcPV2 pseudovirion (PsV) neutralization assay. Furthermore, an EcPV2 L1 virus-like particle (VLP)-based vaccine was generated and its prophylactic efficacy evaluated in vivo . All 6/6 gSCC-affected, but only 3/20 tumor-free age-matched animals revealed EcPV2-neutralizing serum antibody titers by PsV assay. Vaccination of NZW rabbits and BalbC mice with EcPV2 L1 VLP using Freund׳s or alum respectively as adjuvant induced high-titer neutralizing serum antibodies (1600–12,800). Passive transfer with rabbit EcPV2–VLP immune sera completely protected mice from experimental vaginal EcPV2 PsV infection. These findings support the impact of EcPV2 in equine gSCC development and recommend EcPV2 L1 VLP as prophylactic vaccine against EcPV2 infection and associated disease in equids. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
3. RNA-seq analysis in equine papillomavirus type 2-positive carcinomas identifies affected pathways and potential cancer markers as well as viral gene expression and splicing events
- Author
-
Kurt Tobler, Anna Sophie Ramsauer, Claude Favrot, Jakub Kubacki, Mathias Ackermann, Cornel Fraefel, University of Zurich, and Ramsauer, Anna Sophie
- Subjects
Gene Expression Regulation, Viral ,0301 basic medicine ,10253 Department of Small Animals ,Genes, Viral ,Transcription, Genetic ,MMP1 ,RNA Splicing ,030106 microbiology ,Cell ,RNA-Seq ,Context (language use) ,integration ,Biology ,Polymerase Chain Reaction ,genital squamous cell carcinoma ,cancer marker ,Transcriptome ,03 medical and health sciences ,splicing ,seq ,Virology ,Biomarkers, Tumor ,medicine ,Animals ,Horses ,Papillomaviridae ,Gene ,Genetics ,Interleukin-8 ,Papillomavirus Infections ,equine papillomavirus type 2 (EcPV2) ,Cell cycle ,030104 developmental biology ,medicine.anatomical_structure ,DNA, Viral ,RNA splicing ,Carcinoma, Squamous Cell ,2406 Virology ,570 Life sciences ,biology ,RNA ,Horse Diseases ,Matrix Metalloproteinase 1 ,Signal Transduction ,10244 Institute of Virology - Abstract
Equine papillomavirus type 2 (EcPV2) was discovered only recently, but it is found consistently in the context of genital squamous cell carcinomas (SCCs). Since neither cell cultures nor animal models exist, the characterization of this potential disease agent relies on the analysis of patient materials. To analyse the host and viral transcriptome in EcPV2-affected horses, genital tissue samples were collected from horses with EcPV2-positive lesions as well as from healthy EcPV2-negative horses. It was determined by RNA-seq analysis that there were 1957 differentially expressed (DE) host genes between the SCC and control samples. These genes were most abundantly related to DNA replication, cell cycle, extracellular matrix (ECM)-receptor interaction and focal adhesion. By comparison to other cancer studies, MMP1 and IL8 appeared to be potential marker genes for the development of SCCs. Analysis of the viral reads revealed the transcriptional activity of EcPV2 in all SCC samples. While few reads mapped to the structural viral genes, the majority of reads mapped to the non-structural early (E) genes, in particular to E6, E7 and E2/E4. Within these reads a distinct pattern of splicing events, which are essential for the expression of different genes in PV infections, was observed. Additionally, in one sample the integration of EcPV2 DNA into the host genome was detected by DNA-seq and confirmed by PCR. In conclusion, while host MMP1 and IL8 expression and the presence of EcPV2 may be useful markers in genital SCCs, further research on EcPV2-related pathomechanisms may focus on cell cycle-related genes, the viral genes E6, E7 and E2/E4, and integration events.
- Published
- 2019
4. Genital squamous cell carcinoma in men treated by photochemotherapy. A cancer registry-based study from 1978 to 1998.
- Author
-
Aubin, F., Puzenat, E., Arveux, P., Louvat, P., Quencez, E., and Humbert, P.
- Subjects
- *
THERAPEUTIC use of ultraviolet radiation , *MALE reproductive organ cancer , *RADIOTHERAPY - Abstract
Background One single report from the U.S. 16-centre-trial indicated that psoralen and ultraviolet A radiation (PUVA) therapy may induce an increased risk of genital tumours in men, and protection of the genital area is, therefore, recommended. Objectives To evaluate the relevance of this risk in routine clinical practice. Methods Two groups of patients were included in a 1978–98 retrospective study. Case records of men with genital squamous cell carcinoma (SCC) identified from the Cancer Registry of the Doubs area of France were examined for a history of PUVA therapy, topical tar treatment, psoriasis, human papillomavirus infection or genital dermatitis. In addition, all the dermatologists of the Doubs area (in public and private practice) using PUVA therapy were asked to provide information on the number of patients having received PUVA therapy and whether the genital area was exposed during treatment. Results Between 1978 and 1998, among the 48 men who had developed a genital SCC in the Doubs area, only one had a history of intensive PUVA therapy. About 150,000 treatments with PUVA therapy had been performed by 15 dermatologists in the Doubs area for 5400 patients since 1978. No case of genital SCC had been reported, despite the fact that the genital area had not been protected during UVA exposure. Conclusions Although retrospective, our study demonstrates that the occurrence of genital SCC in men treated with PUVA therapy is a very rare event in common dermatological practice. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
5. RNA-seq analysis in equine papillomavirus type 2-positive carcinomas identifies affected pathways and potential cancer markers as well as viral gene expression and splicing events.
- Author
-
Ramsauer AS, Kubacki J, Favrot C, Ackermann M, Fraefel C, and Tobler K
- Subjects
- Animals, Biomarkers, Tumor genetics, Carcinoma, Squamous Cell virology, DNA, Viral genetics, Genes, Viral genetics, Horse Diseases virology, Horses genetics, Horses virology, Interleukin-8 genetics, Matrix Metalloproteinase 1 genetics, Papillomavirus Infections veterinary, Papillomavirus Infections virology, Polymerase Chain Reaction methods, RNA-Seq methods, Transcription, Genetic genetics, Carcinoma, Squamous Cell genetics, Gene Expression Regulation, Viral genetics, Horse Diseases genetics, Papillomaviridae genetics, Papillomavirus Infections genetics, RNA Splicing genetics, Signal Transduction genetics
- Abstract
Equine papillomavirus type 2 (EcPV2) was discovered only recently, but it is found consistently in the context of genital squamous cell carcinomas (SCCs). Since neither cell cultures nor animal models exist, the characterization of this potential disease agent relies on the analysis of patient materials. To analyse the host and viral transcriptome in EcPV2-affected horses, genital tissue samples were collected from horses with EcPV2-positive lesions as well as from healthy EcPV2-negative horses. It was determined by RNA-seq analysis that there were 1957 differentially expressed (DE) host genes between the SCC and control samples. These genes were most abundantly related to DNA replication, cell cycle, extracellular matrix (ECM)-receptor interaction and focal adhesion. By comparison to other cancer studies, MMP1 and IL8 appeared to be potential marker genes for the development of SCCs. Analysis of the viral reads revealed the transcriptional activity of EcPV2 in all SCC samples. While few reads mapped to the structural viral genes, the majority of reads mapped to the non-structural early (E) genes, in particular to E6, E7 and E2/E4. Within these reads a distinct pattern of splicing events, which are essential for the expression of different genes in PV infections, was observed. Additionally, in one sample the integration of EcPV2 DNA into the host genome was detected by DNA-seq and confirmed by PCR. In conclusion, while host MMP1 and IL8 expression and the presence of EcPV2 may be useful markers in genital SCCs, further research on EcPV2-related pathomechanisms may focus on cell cycle-related genes, the viral genes E6, E7 and E2/E4, and integration events.
- Published
- 2019
- Full Text
- View/download PDF
6. Establishment of an in vitro equine papillomavirus type 2 (EcPV2) neutralization assay and a VLP-based vaccine for protection of equids against EcPV2-associated genital tumors
- Author
-
Bettina Huber, Dieter Fink, Christina Schellenbacher, Saeed Shafti-Keramat, Sabine Brandt, and Reinhard Kirnbauer
- Subjects
medicine.medical_treatment ,Antibodies, Viral ,Horse ,Neutralization ,Pseudovirion neutralization assay ,Mice ,Pseudovirion ,Neutralization Tests ,In vivo ,Genital squamous cell carcinoma ,Virology ,medicine ,Animals ,Horses ,Papillomaviridae ,Equus caballus papillomavirus type 2 (EcPV2) ,VLP vaccine ,biology ,Papillomavirus Infections ,Viral Vaccines ,Antibodies, Neutralizing ,In vitro ,Vaccination ,Titer ,Immunology ,Carcinoma, Squamous Cell ,biology.protein ,Female ,Horse Diseases ,Rabbits ,Antibody ,Adjuvant - Abstract
The consistent and specific presence of Equus caballus papillomavirus type 2 (EcPV2) DNA and mRNA in equine genital squamous cell carcinoma (gSCC) is suggestive of an etiological role in tumor development. To further validate this concept, EcPV2-neutralizing serum antibody titers were determined by an EcPV2 pseudovirion (PsV) neutralization assay. Furthermore, an EcPV2 L1 virus-like particle (VLP)-based vaccine was generated and its prophylactic efficacy evaluated in vivo . All 6/6 gSCC-affected, but only 3/20 tumor-free age-matched animals revealed EcPV2-neutralizing serum antibody titers by PsV assay. Vaccination of NZW rabbits and BalbC mice with EcPV2 L1 VLP using Freund׳s or alum respectively as adjuvant induced high-titer neutralizing serum antibodies (1600–12,800). Passive transfer with rabbit EcPV2–VLP immune sera completely protected mice from experimental vaginal EcPV2 PsV infection. These findings support the impact of EcPV2 in equine gSCC development and recommend EcPV2 L1 VLP as prophylactic vaccine against EcPV2 infection and associated disease in equids.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.